Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.03
+14.4%
$0.96
$0.81
$1.76
$24.36M0.74128,475 shs287,538 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.15
+3.9%
$2.29
$1.62
$14.67
$5.10M0.97944,962 shs48,462 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.25
+3.3%
$1.16
$0.51
$5.01
$21.15M1.962.20 million shs79,092 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.68
+0.6%
$1.75
$1.38
$53.79
$20.49M-0.03200,104 shs66,429 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%-6.45%-9.50%-21.30%-38.01%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00%-13.03%-11.54%-46.92%-73.46%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
0.00%-13.57%-16.55%+12.04%+63.96%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.00%-12.11%-5.65%-23.74%-91.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.4595 of 5 stars
3.75.00.00.02.60.81.3
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.3913 of 5 stars
0.04.00.00.02.20.00.0
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.1934 of 5 stars
3.75.00.00.03.60.00.6
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3.4204 of 5 stars
3.14.00.00.04.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00870.87% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.001,034.52% Upside
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$24.711,375.48% Upside

Current Analyst Ratings Breakdown

Latest ENSC, ENLV, QTTB, and MIRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/24/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $7.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.23M2.24N/AN/A($3.10) per share-0.68
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.30 per shareN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$6.65M-3.07N/AN/A$22.47 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$29.07M-$0.66N/AN/AN/AN/A-67.57%-58.45%8/29/2025 (Estimated)
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%8/6/2025 (Estimated)

Latest ENSC, ENLV, QTTB, and MIRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
3/28/2025Q4 2024
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.29-$0.15+$0.14-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
9.71
9.71
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
3.24
3.24
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
6.11
6.11
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.61
6.53
6.53

Institutional Ownership

CompanyInstitutional Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%

Insider Ownership

CompanyInsider Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
6.65%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million18.78 millionOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million1.20 millionNot Optionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.46 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million10.22 millionN/A

Recent News About These Companies

Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart
Piper Sandler Downgrades Q32 Bio (QTTB)
BMO Capital Downgrades Q32 Bio (QTTB)
Q32 Bio downgraded to Neutral from Overweight at Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.03 +0.13 (+14.44%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 +0.01 (+1.46%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.15 +0.08 (+3.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.13 -0.02 (-0.70%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.25 +0.04 (+3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.68 +0.01 (+0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.